Please login to the form below

Not currently logged in
Email:
Password:

Nexavar

This page shows the latest Nexavar news and features for those working in and with pharma, biotech and healthcare.

Roche files Tecentriq/Avastin combo in liver cancer

Roche files Tecentriq/Avastin combo in liver cancer

Patients received PD-L1 inhibitor Tecentriq plus anti-VEGF antibody Avastin or Bayer’s Nexavar (sorafenib) – a standard first-line therapy for HCC.

Latest news

More from news
Approximately 8 fully matching, plus 84 partially matching documents found.

Latest Intelligence

  • Deal Watch table for August 2013 Deal Watch table for August 2013

    Onyx Pharmaceuticals / Amgen. Acquisition. Cancer drugs including Kyprolis, Nexavar and Stivarga.

  • Pharma deals during August 2013 Pharma deals during August 2013

    To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic

  • Intellectual property threats in the BRIC markets Intellectual property threats in the BRIC markets

    The recent upholding of the Indian patent office's rejection of Novartis' Glivec patent application is the latest in a series of actions including the compulsory licence of Nexavar and initiation

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    In its phase 3 trial it was compared with a single rival targeted therapy, Nexavar (sorafenib). ... A benefit was found for Inlyta compared with Nexavar in the cytokine treatment group, on the basis of increased tolerability.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics